In conclusion, this study revealed an appreciable response rate and tolerable toxicity of neoadjuvant anti‐PD‐1/PD‐L1 therapy in triple‐negative breast cancer, lung cancer, and melanoma. This evidence concerns the gene PDCD1 and lung carcinoma.